These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35699971)

  • 1. Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients.
    Bonnet-Serrano F; Poirier J; Vaczlavik A; Laguillier-Morizot C; Blanchet B; Baron S; Guignat L; Bessiene L; Bricaire L; Groussin L; Assié G; Guibourdenche J; Bertherat J
    Eur J Endocrinol; 2022 Aug; 187(2):315-322. PubMed ID: 35699971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
    Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
    Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
    Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone.
    Monaghan PJ; Owen LJ; Trainer PJ; Brabant G; Keevil BG; Darby D
    Ann Clin Biochem; 2011 Sep; 48(Pt 5):441-6. PubMed ID: 21813575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome.
    Verhelst JA; Trainer PJ; Howlett TA; Perry L; Rees LH; Grossman AB; Wass JA; Besser GM
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):169-78. PubMed ID: 1657460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated plasma 19-hydroxyandrostenedione levels in Cushing's disease: stimulation with ACTH and inhibition with metyrapone.
    Mune T; Morita H; Yasuda K; Murayama M; Yamakita N; Miura K
    Clin Endocrinol (Oxf); 1993 Mar; 38(3):265-72. PubMed ID: 8384536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
    Varlamov EV; Han AJ; Fleseriu M
    Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cortisol measurement in patients receiving metyrapone therapy.
    Owen LJ; Halsall DJ; Keevil BG
    Ann Clin Biochem; 2010 Nov; 47(Pt 6):573-5. PubMed ID: 20926474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.
    Daniel E; Aylwin S; Mustafa O; Ball S; Munir A; Boelaert K; Chortis V; Cuthbertson DJ; Daousi C; Rajeev SP; Davis J; Cheer K; Drake W; Gunganah K; Grossman A; Gurnell M; Powlson AS; Karavitaki N; Huguet I; Kearney T; Mohit K; Meeran K; Hill N; Rees A; Lansdown AJ; Trainer PJ; Minder AE; Newell-Price J
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4146-54. PubMed ID: 26353009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased adrenal androgen secretion with inhibition of 11beta-hydroxylase in HIV-infected women.
    Koutkia P; Berry J; Eaton K; Breu J; Grinspoon S
    Am J Physiol Endocrinol Metab; 2006 May; 290(5):E808-13. PubMed ID: 16303845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
    Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
    Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the Quantification of Steroids Androstenedione, Dehydroepiandrosterone, 11-Deoxycortisol, 17-Hydroxyprogesterone, and Testosterone.
    Munar A; Clinton Frazee C; Garg U
    Methods Mol Biol; 2022; 2546():451-457. PubMed ID: 36127612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metyrapone pre-treated inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome.
    Cuneo RC; Lee W; Harper J; Mitchell K; Ward G; Atkinson RL; Salkield I; Cameron DP
    Clin Endocrinol (Oxf); 1997 May; 46(5):607-18. PubMed ID: 9231057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma 11-deoxycortisol, androstenedione, testosterone and ACTH in comparison with the urinary excretion of tetrahydro-11-deoxycortisol as indices of the pituitary-adrenal response to oral metyrapone.
    de Lange WE; Sluiter WJ; Pratt JJ; Doorenbos H
    Acta Endocrinol (Copenh); 1980 Apr; 93(4):488-94. PubMed ID: 6247869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions.
    Melau C; Riis ML; Nielsen JE; Perlman S; Lundvall L; Thuesen LL; Hare KJ; Hammerum MS; Mitchell RT; Frederiksen H; Juul A; Jørgensen A
    BMC Med; 2021 Sep; 19(1):204. PubMed ID: 34493283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease.
    van Aken MO; de Herder WW; van der Lely AJ; de Jong FH; Lamberts SW
    Clin Endocrinol (Oxf); 1997 Aug; 47(2):145-9. PubMed ID: 9302385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the distinction of ectopic and pituitary ACTH dependent Cushing's syndrome by clinical features, biochemical tests and radiological findings.
    Blunt SB; Sandler LM; Burrin JM; Joplin GF
    Q J Med; 1990 Nov; 77(283):1113-33. PubMed ID: 2177207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined use of sodium valproate and metyrapone in the treatment of Cushing's syndrome.
    Nussey SS; Price P; Jenkins JS; Altaher AR; Gillham B; Jones MT
    Clin Endocrinol (Oxf); 1988 Apr; 28(4):373-80. PubMed ID: 2847889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism.
    Ferriere A; Salenave S; Puerto M; Young J; Tabarin A
    Eur J Endocrinol; 2024 Jan; 190(1):L1-L3. PubMed ID: 38123490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approach to the Patient Treated with Steroidogenesis Inhibitors.
    Castinetti F; Nieman LK; Reincke M; Newell-Price J
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.